2020 Top 15 Medical Technology Companies

Avail provides a solution for this kind of surgery: virtualize the presence of multiple people
.
It has built a portable console that connects doctors in the operating room and industry experts anywhere
.
Through multiple remote-controlled high-resolution cameras, external experts can see and hear the operation process and can provide advice to the doctor in real time
.

In addition to accelerating the development cycle of patient procedures and equipment, the console can also provide a level playing field for doctors and hospitals in economically difficult areas
.

Investment: Avail raised US$100 million in its B round of financing in October 2020.
8VC, Baidu Ventures, Coatue, D1 Capital Partners, Lux Capital, Playground Global, Refractor Capital and Sonder Capital also participated in the investment
.

Babson Diagnostics

CEO: David Stein

Established time: 2017

Headquarters: Texas

Part of Babson's long-term cooperation with blood collection heavyweight company BD is focused on a device that is designed to collect laboratory-quality blood samples in places such as pharmacies and grocery stores, and does not require technical staff training
.
The device is also designed to collect only a small amount of blood from finger capillaries without sacrificing the quality of the sample
.

The company is also paying attention to COVID-19 testing, and its antibody testing received emergency authorization from the US FDA in June last year
.
Since then, Babson has used its serological testing technology to provide screening for patients across the United States
.

The company's serological test is being used by medical service providers, and it is currently conducting clinical studies with research centers including the Dell School of Medicine at the University of Texas at Austin
.

Investment: In September 2020, under the leadership of Siemens Healthineers, Prism Ventures, Genesis Merchant Capital and Lago Consulting Group, Babson completed a total of $13.
7 million in Series A financing
.

BenevolentAI

CEO: Joanna Shields

Date of establishment: 2013

Base: London, England, Cambridge, Massachusetts

For many life science companies, being hit hard by the new coronavirus pandemic, research and development efforts have been set aside for months or even years
.

However, for BenevolentAI, COVID became a testing ground for its rapid, artificial intelligence-based drug discovery method, and Eli Lilly tested its arthritis drug Olumiant (baricitinib) during COVID-19
.

In a study published in The Lancet early last year, the BenevolentAI team suggested that Eli Lilly not only reduces inflammation, but also prevents the virus from entering and infecting lung cells by inhibiting a protein called AAK1
.
This prompted Eli Lilly to start Phase 3 trials in the summer.
By October, the combination of the drug and Gilead’s Remdesivir showed that the drug combination can reduce recovery time and improve the clinical efficacy of patients with COVID-19 infection, which is very fast It got the emergency authorization of the US FDA for certain hospitalized patients
.

This technology was further verified earlier this year
.
The company signed an agreement with AstraZeneca.
The Benevolent platform predicted a new chronic kidney disease target from its AI technology.
It was also the project's first artificial intelligence-generated drug to enter the portfolio of the two companies
.

Investment: BenevolentAI was once part of Neil Woodford's investment.
It rebounded from the bankruptcy of the Woodford Equity Income Fund.
Last year, it received a cash injection of US$90 million from Singapore’s sovereign fund Temasek.
Two years ago, the company received some undisclosed Of U.
S.
investors raised $115 million
.

C2N Diagnostics

CEO: Joel Braunstein

Established time: 2007

Headquarters: Missouri

C2N Diagnostics hopes to make the diagnosis of Alzheimer’s easier through its non-invasive blood tests
.
Last year, it launched the blood test PrecivityAD in the United States and recently received a commercialization mark in the European Union
.

The test is ordered by a doctor to perform on patients who are "experiencing memory and thinking problems
.
" Although the test cannot diagnose Alzheimer's disease alone, C2N's non-invasive test can help predict brain pathology in patients with cognitive impairment and can be used as a tool for broader clinical evaluation
.

Investment: Last fall, the C2N project received more than $2.
2 million in funding from the Alzheimer’s Drug Discovery Foundation
.

Canary Medical

CEO: William Hunter

Established time: 2012

Headquarters: Vancouver

Canary Medical is introducing the Internet of Things to medical devices, starting with artificial knees, and its smart implants are designed to provide real-time feedback
.
Eventually, when the company collects enough data from enough patients, it plans to use machine learning to recognize patterns and help doctors find problems, such as infections or loose joints, before they get worse
.
Canary's method provides data from the implant itself, rather than through second-hand means
.

The company's device, called Canturio, is suitable for the "dead space" of an artificial knee and is wrapped in the part of the implant that extends to the tibia or tibia
.
It contains FDA-approved technologies, including pacemaker batteries, micro-sensors based on micro-electromechanical systems, and wireless data transmitters
.
It measures movement, including the patient's gait and the new joint measurement range of interest to the doctor, and is usually captured in a post-operative physical examination snapshot
.

Canary hopes to enter the artificial hip joint in the next few years, then the artificial shoulder joint, and then expand to traumatic screws and vascular implants, such as heart valves or stents
.

These devices may differ in size and functionality, but they are basically based on three components: a power supply, a transmitter, and a sensor array
.
Canary will adjust each part to suit the purpose of each device
.

Investment: Kobuck Co.
, BioSicence Managers LP company, Quark Ventures Limited partnership company and Relentless
.

  
Caption Health

CEO: Charles Cadieu

Established time: 2013

Headquarters: San Francisco

Caption's artificial intelligence can guide any professional action in real time
.

The device can be used in hospital emergency rooms as well as small clinics and doctors' offices, making cardiac ultrasound a widely used technology and service
.
Caption's artificial intelligence allows hospital staff who are already in the room of a COVID-19 patient to perform inspections, instead of calling an expert for every operation, requiring expert participation
.

Caption also won a $4.
95 million grant from the Bill and Melinda Gates Foundation to expand the application of artificial intelligence from heart scanning to lung scanning, which requires a similar level of expertise
.
The goal is to screen young children for potentially fatal cases of pneumonia in underserved communities, as well as to screen patients with other diseases and COVID-19
.

Investment: Caption raised US$53 million from DCVC, Khosla Venture Capital, Atlantic Bridge, and cardiovascular equipment manufacturer Edwards Life Sciences in its Series B financing in July 2020
.

Cue Health

CEO: Ayub Khattak

Established time: 2010

Headquarters: California

The Cue Health point-of-care COVID-19 test is designed to provide a fast turnaround time similar to an antigen test, making it the preferred screening test for the NBA and its players
.

The company's test kit is a single-use, independent unit for the application of reagents and related materials required for molecular detection of the SARS-CoV-2 virus that causes COVID-19
.

In June last year, authorized by the US FDA, Cue’s handheld diagnostic device uses a nasal swab and a cartridge-based reader to transmit the results to a connected smartphone app in about 20 minutes
.

Just this month, Cue received a new milestone authorization from the US FDA, allowing molecular testing for COVID-19 at home without a prescription
.

Investment: In June 2020, with the support of Decheng Capital, Foresite Capital, Madrone Capital Partners, ACME Capital, Johnson & Johnson Innovation and other companies, the company raised US$100 million through Series C financing, and obtained BARDA’s US$13 million portable COVID-19 test supply contract
.
In October 2020, the U.
S.
Department of Defense and the Department of Health added $481 million in rewards to Cue
.

   
CVRx

CEO: Nadim Yared

Established time: 2001

Headquarters: Minneapolis

Most treatments for heart failure focus on reducing the load on the heart, or directly relieving cardiovascular symptoms
.
Traditionally, they are divided into two categories: one is drugs that make it easier for the heart to pump blood throughout the body, and the other is devices that use electricity to help control the heart rhythm
.

CVRx uses a different angle to treat heart failure by sending different messages to the brain, rather than creating a device that interacts with the heart, which brings various risks
.

The body is accelerating most of the time and not getting enough rest.
CVRx's barosim aims to lower the sympathetic nervous system and at the same time strengthen the parasympathetic nervous system
.
This device is implanted under the clavicle, and the wire is connected to the carotid artery in the neck
.
It works by sending electrical pulses to the baroreceptors on the arterial wall, inducing the brain to think that it is not getting enough oxygen
.

Investments: Action Potential Venture Capital, DaVita HealthCare Partners, Gilde HealthCare Partners, Hatteras Venture Partners, Johnson & Johnson Innovations, New Enterprise Associates, Treo Ventures, Venrock, Vensana Capital, Windham Venture Partners and Ysios Capital
.

Ellume

CEO: Sean Parsons

Established time: 2010

Headquarters: Brisbane

The Australian company Ellume has developed the first COVID-19 test that can be sold over the counter in the United States without a doctor's prescription
.
It is funded by the Accelerated Diagnosis Initiative of the National Institutes of Health
.

Consumers can purchase a ready-made Ellume test
.
Once the instrument has collected a valid sample, accurate results can be obtained in about 15 minutes
.
A simulated clinical research trial showed that 96% of the positive results were consistent with the more complex standard of care RT-PCR test, while the negative rate of symptomatic people was 100%, and the incidence of asymptomatic individuals was 91% and 96%, respectively
.

Ellume's test equipment works in conjunction with a smartphone app.
The smartphone app provides step-by-step instructions on how to perform the test and displays the results after the test is complete
.
Because it is completely digitally connected, data can be automatically sent to health authorities, providing an additional means for tracking diseases
.

In addition to consumer-oriented tests, Ellume has also partnered with Qiagen to provide portable digital COVID antibody and antigen tests for healthcare professionals
.

Foldax

CEO: Frank Maguire

Established time: 2013

Headquarters: Utah

Foldax is developing three Tria valves, which reshape the image of heart valves by adding new biopolymers and positioning-specific valve designs.
The goal is to use them for a lifetime without relying on anticoagulants
.

The company's first product is the aortic surgery heart valve.
After the FDA conducted an expanded study in October last year, it is currently conducting a clinical study in the United States
.
The second device is a mitral valve surgery valve, which was approved by the US FDA for testing in the United States at the end of 2020
.
The third product is transcatheter aortic valve replacement in the preclinical trial stage
.

What makes this company strong is not only the technology itself, but also the manufacturing process
.
The company’s robotic manufacturing only accounts for less than 5% of the space required for tissue valve manufacturing, and less than 1% of the personnel required to manufacture the same number of valves
.

Investment: Foldax raised US$20 million in Series D financing in 2020, led by MemorialCare Innovation Fund, Angel Doctor Fund, Sayan Bioventures, BioStar Capital, Kairos Ventures and Caltech provided additional donations
.

  
Hyperfine Research

Chairman and Founder: Jonathan Rothberg

Established time: 2014

Headquarters: New York City and Connecticut

The SWOP system launched by the company is not only a redesign of a typical hospital scanner over 20,000 pounds, but also a brand-new diagnostic method.
It is built to compete with relatively flexible and versatile X-ray and CT machines
.

Hyperfine's scanner is the world's first small, light weight, elevator-mounted MRI, and it is designed to be rolled up to the patient's bedside for brain scanning
.
It can be plugged into a daily power outlet and controlled by a dedicated iPad
.

It may be especially useful for patients in the intensive care unit or at high risk of stroke
.
It allows the scanner to be brought to them, instead of transferring it to the basement radiology department through the hospital, patients can be treated and still be surrounded by life-sustaining machines and their staff
.

Since then, Hyperfine has also provided a license for artificial intelligence software that can alert signs of trauma, including midline movement, separating the cerebral hemispheres, and measuring cavities filled with cerebrospinal fluid
.

Investment: Hyperfine recently raised $90 million in its D round of financing in February.
Its backers include GV (formerly Google Ventures), as well as Nextrans, Axiom Associates, Huami, Colle Capital, LSS, and Altium Capital
.

  IsoPlexis

CEO: Sean Mackay

Established time: 2013

Headquarters: Connecticut

IsoPlexis hopes to make single-cell analysis easier to connect with the recently launched desktop IsoSpark instrument, and its products are designed for use in large and small laboratories
.
The company's hardware can simultaneously label hundreds of individual cells with antibody-based barcodes and classify each cell based on all the proteins they secrete
.

This work can help discover previously hidden cell types, which may be overactive factors that cause a certain disease, or those that may change the way the body comes into contact with a particular drug
.

The company also joined the Coronavirus Research Consortium led by the Institute of Systems Biology, Merck and the Swedish Medical Center in Seattle, working with Gilead, Adaptive, 10x Genomics, Metabolon, Stanford University and other institutions to reveal the molecular work of the virus.
Mechanism
.

Investors: Isolexis raised $85 million in equity financing in its D round of financing in January, plus $50 million in credit, including support from Perceptive Advisors, Ally Bridge Group, BlackRock and other investors
.

Mammoth Biosciences

CEO: Trevor Martin

Established time: 2017

Headquarters: California

Mammoth has acquired technical equipment from the laboratory of its co-founder, CRISPR pioneer and Nobel Prize winner Jennifer Doudna.
The company is building a biological, customizable search engine for clinicians and researchers
.

In diagnosis, the application is relatively simple: when a CRISPR enzyme programmed for a specific gene coding sequence matches its target, it will act and release a signal, which will be shown as a positive result in the test
.
This is expected to provide the same accurate results as PCR testing, while ultimately requiring less hardware and laboratory resources
.

The company first obtained emergency authorization from the US FDA in August last year to produce a CRISPR kit that allows manual COVID detection using standard well plates
.
GlaxoSmithKline is also developing a one-time over-the-counter drug
.

Mammoth's goals include plans to develop its reagents into composite tests that can scan multiple diseases at the same time, as well as a toolkit for genome editing and discovery of new CRISPR protein systems
.
It has begun to develop a handheld screener for the U.
S.
Department of Defense to test at least 10 pathogens, as well as laboratory tests that simultaneously analyze clinical and environmental samples from more than 1,000 disease targets
.

Investment: In January 2020, the Series B financing raised US$45 million, led by Decheng Capital, and supported by companies such as Mayfield, NFX, Verily, Brook Byers, Plum Alley, Pacific 8, and aMoon
.

 
Paige

CEO: Leo Grady

Established time: 2017

Headquarters: New York City

Paige's project is based on tumor slides that have been digitized by the cancer center over the years, plus millions of slides extracted from its archives, and then searched and traced to genes that may affect the patient's prognosis or treatment
.

The company's software can scan breast and prostate tissue samples for suspicious features, becoming a European approved clinical diagnostic project and a breakthrough designated project by the US FDA
.

In November last year, Paige collaborated with genome detection company Agendia to combine its digital pathology project with breast tumor tissue sequencing to establish new cancer biomarkers derived from artificial intelligence
.

Investment: In January last year, a $100 million round of C round of financing raised funds from Casdin Capital and Johnson & Johnson Innovations, while last year’s months-long Series B financing raised 70 million from institutions such as Goldman Sachs and medical venture capital partners.
US dollars
.